|
US 12,403,196 B2 |
|
| Ras inhibitors |
| Elena S. Koltun, Foster City, CA (US); James Cregg, Belmont, CA (US); Yang Liu, Foster City, CA (US); and Adrian L. Gill, Atherton, CA (US) |
| Assigned to Revolution Medicines, Inc., Redwood City, CA (US) |
| Filed by Revolution Medicines, Inc., Redwood City, CA (US) |
| Filed on Feb. 25, 2025, as Appl. No. 19/062,331. |
| Application 19/062,331 is a continuation of application No. 18/188,966, filed on Mar. 23, 2023, granted, now 12,280,113. |
| Application 18/188,966 is a continuation of application No. 17/476,269, filed on Sep. 15, 2021, granted, now 11,690,915, issued on Jul. 4, 2023. |
| Claims priority of provisional application 63/192,775, filed on May 25, 2021. |
| Claims priority of provisional application 63/184,412, filed on May 5, 2021. |
| Claims priority of provisional application 63/129,231, filed on Dec. 22, 2020. |
| Claims priority of provisional application 63/078,802, filed on Sep. 15, 2020. |
| Prior Publication US 2025/0186590 A1, Jun. 12, 2025 |
| This patent is subject to a terminal disclaimer. |
| Int. Cl. A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07D 417/14 (2006.01) |
